Huntsville-based biotech firm Discovery Life Sciences has acquired ReachBio Research Labs. The Seattle-based ReachBio specializes in cell-based assays, predictive hematotoxicity and drug screening services.
Discovery says the acquisition will allow it to give its customers a broader range of cell biology services.
ReachBio, founded in 2007, has focused its cell biology work on blood and bone marrow stem cell assays, providing immune response and toxicity assessments related to blood diseases, cell and gene therapy, immunology, oncology and more.
With new FDA regulations that limit animal testing requirements, ReachBio’s assays should allow Discovery to accelerate its research, the company says. “We are thrilled to welcome ReachBio to the Discovery family,” said Discovery CEO Glenn Bilawsky. “ReachBio’s expertise in cell-based assays and drug screening favorably positions us to capitalize on the recent regulatory changes and continue to meet the rapidly evolving needs of the pharmaceutical industry.”
“Joining forces with Discovery is an exciting opportunity for us,” said Emer Clarke, Ph.D., ReachBio‘s chief scientific officer. “We share Discovery’s passion for science and believe that combining our expertise in cell-based assays and drug screening with Discovery’s broad multi-omics capabilities will enable us to provide a broader and more strategic range of services to clients in the pharmaceutical industry. Together, we will further accelerate the advancement of drug discovery and development to improve patient outcomes.”
